Ozempic vs Mounjaro for Type 2 Diabetes: The 2026 Head-to-Head

The short answer

Ozempic and Mounjaro are the two dominant once-weekly injectable GLP-1-class medications for type 2 diabetes. Ozempic is semaglutide, a GLP-1 receptor agonist, from Novo Nordisk. Mounjaro is tirzepatide, a dual GIP/GLP-1 receptor agonist, from Eli Lilly. The head-to-head SURPASS-2 trial showed Mounjaro produces greater HbA1c reduction and greater weight loss. Ozempic has stronger cardiovascular outcomes evidence.

Both are approved for type 2 diabetes management as adjuncts to diet and exercise. Neither is on-label for weight loss specifically (that's Wegovy for semaglutide and Zepbound for tirzepatide).

SURPASS-2: the head-to-head trial that settled the efficacy question

The SURPASS-2 trial (Frías et al., NEJM 2021) directly compared tirzepatide against semaglutide in adults with type 2 diabetes on metformin monotherapy. 1,879 participants randomized to tirzepatide 5 mg, 10 mg, 15 mg, or semaglutide 1 mg weekly for 40 weeks.

HbA1c reduction from baseline:

• Tirzepatide 5 mg: -2.0%
• Tirzepatide 10 mg: -2.2%
• Tirzepatide 15 mg: -2.3%
• Semaglutide 1 mg: -1.9%

Weight loss from baseline:

• Tirzepatide 5 mg: -7.6 kg (~17 lb)
• Tirzepatide 10 mg: -9.3 kg (~20 lb)
• Tirzepatide 15 mg: -11.2 kg (~25 lb)
• Semaglutide 1 mg: -5.7 kg (~13 lb)

Tirzepatide beat semaglutide on both endpoints across all doses. The gap widens at higher tirzepatide doses. For a diabetic patient prioritizing maximum glycemic control and weight loss, Mounjaro is the stronger clinical choice based on head-to-head data.

Cardiovascular evidence: where Ozempic leads

Ozempic has completed cardiovascular outcomes trials that demonstrate benefit beyond glycemic control. Mounjaro's cardiovascular outcomes trial is still running.

SUSTAIN 6 (Marso et al., NEJM 2016): 3,297 patients with type 2 diabetes at high cardiovascular risk. Semaglutide reduced the primary composite cardiovascular endpoint (cardiovascular death, non-fatal MI, non-fatal stroke) by 26% vs placebo over 2.1 years. Established cardiovascular protection for semaglutide in diabetes.

SELECT (Lincoff et al., NEJM 2023): Semaglutide 2.4 mg (Wegovy dose) reduced major cardiovascular events by 20% in adults with obesity and established cardiovascular disease (without diabetes). Extends semaglutide's cardiovascular protection to the obesity population.

SURPASS-CVOT: The tirzepatide cardiovascular outcomes trial. Ongoing. Results expected 2026-2027. This will determine whether tirzepatide's superior weight and glycemic effects translate to cardiovascular protection at least equivalent to semaglutide's.

Clinical implication: Some cardiologists specifically prefer Ozempic for patients with established cardiovascular disease based on SUSTAIN 6 evidence. If tirzepatide shows cardiovascular protection in SURPASS-CVOT, this preference may shift. Until then, Ozempic has the stronger cardiovascular dossier.

Kidney disease evidence: FLOW trial

Another Ozempic-specific evidence advantage comes from the FLOW trial in diabetic kidney disease.

FLOW (Perkovic et al., NEJM 2024): Semaglutide reduced major kidney disease events by 24% in patients with type 2 diabetes and chronic kidney disease. This established renal protection in a population at high risk for kidney disease progression.

Mounjaro doesn't have equivalent completed kidney outcomes data yet. For diabetic patients with existing kidney disease, Ozempic has a specific evidence-based indication that Mounjaro doesn't.

Mechanism: single vs dual receptor agonism

The mechanistic difference is why efficacy differs.

Ozempic (semaglutide) activates the GLP-1 receptor. GLP-1 signaling suppresses appetite, slows gastric emptying, promotes glucose-dependent insulin release, and inhibits glucagon secretion. The result: better glycemic control and modest weight loss.

Mounjaro (tirzepatide) activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. Adding GIP agonism to GLP-1 agonism produces greater weight loss and better glycemic control. GIP's role has been debated (Amgen's MariTide program tests whether GIP antagonism might be even better) but the empirical result is clear: dual agonism outperforms single agonism in the head-to-head trials.

The mechanistic sophistication of tirzepatide reflects a generation of drug development progress. Whether triple agonism (GLP-1 + GIP + glucagon, like retatrutide) will further extend that gain is being tested in the Phase 3 TRIUMPH program.

Side effects

Both drugs share the standard incretin class side-effect pattern. GI symptoms during dose escalation dominate the tolerability discussion.

Nausea: Around 20-25% incidence on Ozempic; around 12-24% on Mounjaro across dose arms. Somewhat lower on Mounjaro on average.

Diarrhea, vomiting, constipation: Similar rates on both drugs, generally in the 10-25% range during titration.

Injection site reactions: Uncommon on both.

Hypoglycemia: Rare when used as monotherapy for diabetes. Rises substantially when combined with insulin or sulfonylureas. For patients on those medications, dose adjustment of the co-medication is often necessary.

Gallbladder events: Elevated risk with both drugs, primarily related to the associated weight loss rather than direct drug effects.

Thyroid C-cell tumors: Boxed warning on both. Rodent signal; no compelling human evidence.

Pancreatitis: Very rare on both. Patients with prior pancreatitis should discuss specific risk.

Anesthesia interaction: Both drugs delay gastric emptying and require preoperative pause for procedures requiring sedation. See our drug interactions article for the current ASA guidance.

Dosing patterns

Ozempic titration: Start 0.25 mg weekly for 4 weeks, then 0.5 mg for at least 4 weeks. Can increase to 1 mg or 2 mg based on clinical response. Maintenance doses of 0.5, 1, and 2 mg weekly.

Mounjaro titration: Start 2.5 mg weekly for 4 weeks, then escalate by 2.5 mg every 4 weeks based on tolerability. Available doses: 2.5, 5, 7.5, 10, 12.5, and 15 mg weekly. Maintenance doses of 5-15 mg depending on clinical goals.

Mounjaro's wider dose range provides more flexibility for individualized therapy. For patients tolerating incretin medications well who need aggressive glycemic control, higher Mounjaro doses often produce better outcomes than maximum Ozempic doses.

Cost and coverage

List prices are similar: approximately $968-1,000/month for Ozempic; approximately $1,000-1,100/month for Mounjaro.

Commercial insurance: Both are generally covered for type 2 diabetes with prior authorization. Coverage often includes step therapy requirements (trying metformin, sulfonylurea, or other options first). Copay ranges from $25 to $200+ depending on plan tier.

Savings programs:

• Novo Nordisk offers Ozempic savings cards for commercially-insured patients (up to $150 savings per fill).
• Lilly offers Mounjaro savings cards for commercially-insured patients (as low as $25/month for eligible patients).

Cash pay:

• Ozempic cash pay is expensive without insurance; NovoCare has direct-to-patient options but they're structured for specific patient populations.
• Mounjaro cash pay is similarly expensive; LillyDirect offers Zepbound vials at $349-499/month but this is the obesity indication product, not diabetes-indication Mounjaro. Cash-pay Mounjaro directly is more limited.

Medicare Part D: Both are covered under most plans for diabetes; specific formulary status varies.

Medicaid: Coverage varies by state.

Which is right for a specific patient?

Choose Mounjaro when:

• Maximum HbA1c reduction is the priority
• Substantial weight loss is a clinical goal (comorbid obesity)
• Patient can tolerate the wider dose range for individualization
• Cardiovascular disease is not established (Ozempic's advantage there doesn't apply)
• Kidney disease is not established (Ozempic's FLOW advantage doesn't apply)
• Insurance covers Mounjaro on formulary

Choose Ozempic when:

• Established cardiovascular disease (SUSTAIN 6, SELECT evidence)
• Diabetic kidney disease (FLOW trial evidence)
• Insurance coverage favors Ozempic
• Patient responds well to lower-dose GLP-1 monotherapy
• Patient prefers the specific evidence base of semaglutide

Either works when:

• The differences don't materially affect the specific patient's clinical situation
• Coverage is equivalent and the patient has no strong preference
• Prescriber comfort or clinic protocol drives the choice

What to discuss with your prescriber

• Your current HbA1c and weight-loss goals
• Your cardiovascular disease history
• Your kidney function (eGFR, urine albumin)
• Your insurance coverage of both drugs
• Your history with other GLP-1 medications if any
• Concurrent medications (especially insulin, sulfonylureas)
• Planned surgeries (both require preoperative pause)
• Cost considerations if insurance coverage is limited

Related reading

For the deeper mechanism comparison, see Semaglutide vs Tirzepatide for weight loss. For brand-name understanding, see Mounjaro vs Zepbound (Mounjaro is diabetes-indication tirzepatide, Zepbound is obesity-indication tirzepatide, same molecule) and Semaglutide brand names. For the emerging pipeline that may reshape this comparison, see our GLP-1 pipeline 2026 and beyond coverage.